Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia2006 · 293 citations
2. 2Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes2011 · 90 citations
3. 3<i>JAK2</i>V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events2014 · 55 citations
4. 4Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms2015 · 272 citations